Table 4. Genotyping frequency of FGFR4 rs351855 polymorphism on clinical statuses with oral cancer.

Clinical stage			OR (95% CI)	p Value	AOR (95% CI)a	p Value
FGFR4 rs351855	Stage I/II (n=467) n (%)	Stage III/IV (n=488) n (%)
GG	98 (21.0%)	127 (26.0%)	1.000 (reference)		1.000 (reference)
GA	257 (55.0%)	267 (54.7%)	0.802 (0.585-1.098)	p=0.168	0.797 (0.581-1.093)	p=0.159
AA	112 (24.0%)	94 (19.3%)	0.648 (0.443-0.947)	p=0.025*	0.637 (0.435-0.933)	p=0.021*
Tumor size
FGFR4 rs351855	<T2 (n=551) n (%)	> T2 (n=404) n (%)
GG	122 (22.1%)	103 (25.5%)	1.000 (reference)		1.000 (reference)
GA	304 (55.2%)	220 (54.5%)	0.857 (0.626-1.174)	p=0.337	0.860 (0.628-1.178)	p=0.348
AA	125 (22.7%)	81 (20.0%)	0.768 (0.523-1.126)	p=0.176	0.767 (0.522-1.126)	p=0.175
Lymph node metastasis
FGFR4 rs351855	No (n=648) n (%)	Yes (n=307) n (%)
GG	148 (22.8%)	77 (25.1%)	1.000 (reference)		1.000 (reference)
GA	353 (54.5%)	171 (55.7%)	0.931 (0.669-1.296)	p=0.672	0.928 (0.666-1.292)	p=0.658
AA	147 (22.7%)	59 (19.2%)	0.771 (0.513-1.161)	p=0.213	0.765 (0.508-1.153)	p=0.201
Metastasis
FGFR4 rs351855	M0 (n=944) n (%)	M1 (n=11) n (%)
GG	221 (23.4%)	4 (36.4%)	1.000 (reference)		1.000 (reference)
GA	520 (55.1%)	4 (36.4%)	0.425 (0.105-1.715)	p=0.229	0.415 (0.102-1.680)	p=0.218
AA	203 (21.5%)	3 (27.2%)	0.816 (0.181-3.692)	p=0.792	0.783 (0.172-3.559)	p=0.751
Cell differentiation
FGFR4 rs351855	Well (n=151) n (%)	Moderate/poor (n=804) n (%)
GG	33 (21.9%)	192 (23.9%)	1.000 (reference)		1.000 (reference)
GA	87 (57.6%)	437 (54.4%)	0.863 (0.559-1.334)	p=0.580	0.865 (0.559-1.338)	p=0.515
AA	31 (20.5%)	175 (21.7%)	0.970 (0.570-1.651)	p=0.911	0.982 (0.577-1.674)	p=0.948

^a Adjusting for the effects of betel quid chewing, cigarette smoking and alcohol drinking.